After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals
Thelin is Encysive's only in-house marketed drug. It treats a condition called pulmonary arterial hypertension (PAH) and is approved for marketing in the European Union and a few other places around the world, but not in the United States. Sales guidance provided by Encysive calls for 2007 sales to be a bit above the company's previous $10.5 million to $11.5 million forecast, with 2008 estimates for worldwide sales in the $40 million to $50 million range.
Last week, both of Encysive's most direct competitors, Actelion and Gilead Sciences
Sales of other PAH treatments have been strong as well in the fourth quarter. Gilead's Letairis, which is only approved in the U.S., brought in a respectable $15 million in the fourth quarter, in only its second full quarter on the market. Sometimes competitor and sometimes complementary treatment Revatio (known more commonly as Viagra) from Pfizer
Almost every approved PAH treatment has shown strong sales growth in recent quarters, and there are a host of drugmakers, like United Therapeutics
Pulmonary arterial hypertension is a market that is undoubtedly (and unfortunately) experiencing a large market expansion as more and more patients are correctly diagnosed and put on PAH drugs. The market opportunity in the U.S. and Europe is huge.
It will probably be another two years before Encysive's Thelin will be on the market in the United States, because the FDA wants more efficacy data before approving it. Encysive is planning to begin a phase 3 study in the second quarter. The main question now is what highly diluted shape Encysive will be in by the time Thelin gets to the U.S. market.
More from The Motley Fool
Why Palo Alto Networks, Inc. Stock Climbed 15.9% in 2017
Despite some sales hiccups early on, the leader in next-gen security platforms just capped a stellar year.
Why A10 Networks Shares Plunged Today
The networking company's fourth-quarter revenue fell shy of guidance.
What Investors Want to See From Zoe’s Kitchen in 2018
After a terrible 2017, can the fast-casual Mediterranean chain bounce back?